• Written informed consent according to International Conference on Harmonisation (ICH)/ Good Clinical Practice (GCP) regulations before registration and prior to any trial specific procedures.

• Biochemical recurrence occurring at least 2 years after external radiotherapy to the prostate lodge and the end of hormone therapy, for prostatic adenocarcinoma previously treated by radical prostatectomy.

• Local recurrence in irradiated areas proven by biological (PSA \> 0.2 ng/ml and ascending confirmed by at least 2 successive assays) and radiological (lesion visible on MRI and/or Choline PET and/or Prostate-Specific Membrane Antigen (PSMA) PET).

• Recurrence without rectal invasion

• Pelvic and prostate MRI evaluation

• Absence of pelvic lymph node or metastatic recurrence proven by choline PET or PSMA PET scan

• World Health Organisation (WHO) performance status 0-1

• Low risk, intermediate risk and high risk with a single risk factor

• PSA doubling time \> 6 months

• No anti-cancer treatments planned for the current relapse, including hormone therapy.

• Age \> 18 years old.

• Life expectancy greater than or equal to 5 years.

• Patient registered with a health insurance system.

• Patients willing and able to comply with the planned visits, treatment plan, laboratory tests and other study procedures indicated in the protocol.